Holen Sie sich die Stockscreener-App
1.59
6.47%
-0.11
Handel nachbörslich:
1.59
Schlusskurs vom Vortag:
$1.70
Offen:
$1.59
24-Stunden-Volumen:
30,656
Relative Volume:
1.01
Marktkapitalisierung:
$8.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.3985
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
-22.06%
1M Leistung:
-31.76%
6M Leistung:
-39.31%
1J Leistung:
-74.76%
1-Tages-Spanne:
$1.5601
$1.70
1-Wochen-Bereich:
$1.5601
$2.0981
52-Wochen-Spanne:
$1.5601
$6.40
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.59 | 8.64M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com India
Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
What is Wedbush’s Estimate for APRE FY2025 Earnings? - The AM Reporter
Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World
APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks
Aprea Therapeutics repots Q4 EPS (49c) vs. (92c) last year - TipRanks
Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo
MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online
Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India
Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com
Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Ault Global (NYSEAMERICAN:DPW) Enters into Exchange Agreement with Orchid Finance LLC – Converts Outstanding Term Note for Convertible Promissory NoteThe financial landscape of Ault Global, trading under the ticker symbol DPW on the NYSE Amer - Defense World
Aprea Therapeutics Announces Update to Patent Portfolio in DNA Damage Response Cancer TherapeuticsDOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) provided an update on its existing patent portf - Defense World
FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment - MSN
Aprea Therapeutics provides update on existing patent portfolio - Yahoo Finance
Aprea Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com South Africa
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail
APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):